Zevra Therapeutics (NASDAQ:ZVRA) Issues Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) announced its earnings results on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10, FiscalAI reports. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The company had revenue of $37.76 million for the quarter, compared to analyst estimates of $37.08 million.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• MIPLYFFA sales accelerated: Third-quarter revenue rose 45% year over year to $37.8 million, including $34 million in U.S. MIPLYFFA sales, which increased 12.6% from Q2. The company reported 197 cumulative prescription enrollment forms, 69% payer coverage, and strong refill and retention rates.
• Zevra believes the U.S. NPC market may be larger than its original estimate of 300–350 diagnosed patients, citing a steady flow of newly diagnosed patients and claims-data analysis. It modestly expanded its commercial team and plans to submit an sNDA in the first quarter of 2027 to potentially include patients younger than 24 months.
• The European review of arimoclomol is ongoing, with an expert group and the CHMP expected to evaluate the data; Zevra continues to expect a CHMP opinion in the fourth quarter. The outcome remains a significant regulatory uncertainty for expanding MIPLYFFA access in Europe.
• Zevra ended the quarter with $270.9 million in cash, cash equivalents, and investments, up $10.7 million sequentially, and reported net income of $19.2 million. The company said its balance sheet provides flexibility to expand MIPLYFFA access and advance its pipeline, including the 72-patient celiprolol DiSCOVER trial, which has recorded four confirmed events to date.

Zevra Therapeutics Trading Up 1.6%

Zevra Therapeutics stock opened at $10.26 on Wednesday. The firm has a market capitalization of $609.24 million, a P/E ratio of 11.15 and a beta of 1.01. Zevra Therapeutics has a twelve month low of $8.01 and a twelve month high of $15.03. The stock’s fifty day simple moving average is $11.11 and its 200-day simple moving average is $10.75.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 revenue increased 45% to $37.8 million, including $34.0 million from MIPLYFFA. Earnings and revenue topped consensus estimates, and Zevra posted its fourth consecutive quarterly earnings beat. Zevra Q3 revenue rises as MIPLYFFA sales grow Zevra Q3 earnings and revenues beat estimates
• Neutral Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, while an opinion from Europe’s CHMP remains expected in Q4. These are potential future catalysts, but their outcomes and timing remain uncertain. Zevra anticipates MIPLYFFA sNDA filing in Q1 2027

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ZVRA shares. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a report on Thursday, August 20th. Guggenheim lowered their target price on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Finally, William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $27.14.

Insiders Place Their Bets

In related news, CEO Neil McFarlane sold 20,000 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the transaction, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 3.70% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.